AR and neoplasm: However, other studies indicated that Doc might interrupt microtubule-dependent trafficking of androgen receptor (AR) into the nuclei, and clinical data also linked cytoplasmic AR in circulating tumor cells with patients’ responses to Doc-chemotherapy.